{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:59:59Z","timestamp":1790755199446,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T00:00:00Z","timestamp":1513641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T00:00:00Z","timestamp":1513641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The treatment of progressive multiple sclerosis (MS) is unsatisfactory. One reason is that the drivers of disease, which include iron-mediated neurotoxicity, lymphocyte activity, and oxidative stress, are not simultaneously targeted. Here we present a systematic screen to identify generic, orally available medications that target features of progressive MS. Of 249 medications that cross the blood\u2013brain barrier, 35 prevent iron-mediated neurotoxicity in culture. Of these, several antipsychotics and antidepressants strongly reduce T-cell proliferation and oxidative stress. We focus on the antidepressant clomipramine and found that it additionally inhibits B-lymphocyte activity. In mice with experimental autoimmune encephalomyelitis, a model of MS, clomipramine ameliorates clinical signs of acute and chronic phases. Histologically, clomipramine reduces inflammation and microglial activation, and preserves axonal integrity. In summary, we present a systematic approach to identify generic medications for progressive multiple sclerosis with the potential to advance rapidly into clinical trials, and we highlight clomipramine for further development.<\/jats:p>","DOI":"10.1038\/s41467-017-02119-6","type":"journal-article","created":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T10:50:36Z","timestamp":1512384636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic"],"prefix":"10.1038","volume":"8","author":[{"given":"Simon","family":"Faissner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak K.","family":"Kaushik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Rauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luanne","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Wee","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,19]]},"reference":[{"key":"2119_CR1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nrneurol.2015.14","volume":"11","author":"RM Ransohoff","year":"2015","unstructured":"Ransohoff, R. M., Hafler, D. A. & Lucchinetti, C. F. Multiple sclerosis\u2014a quiet revolution. Nat. Rev. Neurol. \n                           11, 134\u2013142 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"2119_CR2","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","volume":"387","author":"F Lublin","year":"2016","unstructured":"Lublin, F. et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet \n                           387, 1075\u20131084 (2016).","journal-title":"Lancet"},{"key":"2119_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban, X. et al. Ocrelizumab vs. placebo in primary progressive multiple sclerosis. New Engl. J. Med. \n                           376, 209\u2013220 (2017).","journal-title":"New Engl. J. Med."},{"key":"2119_CR4","unstructured":"Kappos L. et al. Efficacy and safety of siponimod in secondary progressive multiple sclerosis\u2014results of the placebo controlled, double-blind, Phase III EXPAND study. ECTRIMS Online Library (2016)."},{"key":"2119_CR5","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","volume":"8","author":"H Lassmann","year":"2012","unstructured":"Lassmann, H., van Horssen, J. & Mahad, D. Progressive multiple sclerosis: pathology and pathogenesis. Nat. Rev. Neurol. \n                           8, 647\u2013656 (2012).","journal-title":"Nat. Rev. Neurol."},{"key":"2119_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ana.22109","volume":"69","author":"GR Campbell","year":"2011","unstructured":"Campbell, G. R. et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann. Neurol. \n                           69, 481\u2013492 (2011).","journal-title":"Ann. Neurol."},{"key":"2119_CR7","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1177\/1352458514544537","volume":"20","author":"GR Campbell","year":"2014","unstructured":"Campbell, G. R., Worrall, J. T. & Mahad, D. J. The central role of mitochondria in axonal degeneration in multiple sclerosis. Mult. Scler. \n                           20, 1806\u20131813 (2014).","journal-title":"Mult. Scler."},{"key":"2119_CR8","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/brain\/aws012","volume":"135","author":"MT Fischer","year":"2012","unstructured":"Fischer, M. T. et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain \n                           135, 886\u2013899 (2012).","journal-title":"Brain"},{"key":"2119_CR9","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/ana.23974","volume":"74","author":"S Hametner","year":"2013","unstructured":"Hametner, S. et al. Iron and neurodegeneration in the multiple sclerosis brain. Ann. Neurol. \n                           74, 848\u2013861 (2013).","journal-title":"Ann. Neurol."},{"key":"2119_CR10","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.autrev.2016.07.008","volume":"15","author":"J Fraussen","year":"2016","unstructured":"Fraussen, J., de Bock, L. & Somers, V. B cells and antibodies in progressive multiple sclerosis: contribution to neurodegeneration and progression. Autoimmun. Rev. \n                           15, 896\u2013899 (2016).","journal-title":"Autoimmun. Rev."},{"key":"2119_CR11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","volume":"14","author":"B Serafini","year":"2004","unstructured":"Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E. & Aloisi, F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. \n                           14, 164\u2013174 (2004).","journal-title":"Brain Pathol."},{"key":"2119_CR12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/ana.1255","volume":"50","author":"JW Prineas","year":"2001","unstructured":"Prineas, J. W. et al. Immunopathology of secondary-progressive multiple sclerosis. Ann. Neurol. \n                           50, 646\u2013657 (2001).","journal-title":"Ann. Neurol."},{"key":"2119_CR13","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ana.24497","volume":"78","author":"JM Frischer","year":"2015","unstructured":"Frischer, J. M. et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann. Neurol. \n                           78, 710\u2013721 (2015).","journal-title":"Ann. Neurol."},{"key":"2119_CR14","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2174\/18715273113126660177","volume":"12","author":"S Samanani","year":"2013","unstructured":"Samanani, S. et al. Screening for inhibitors of microglia to reduce neuroinflammation. CNS Neurol. Disord. Drug Targets \n                           12, 741\u2013749 (2013).","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"2119_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ana.24408","volume":"78","author":"M Komori","year":"2015","unstructured":"Komori, M. et al. Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis. Ann. Neurol. \n                           78, 3\u201320 (2015).","journal-title":"Ann. Neurol."},{"key":"2119_CR16","doi-asserted-by":"crossref","unstructured":"Faissner S. et al. Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: prospective combination treatment for progressive disease? Mult. Scler. (Houndmills, Basingstoke), 1352458517728811 (2017).","DOI":"10.1177\/1352458517728811"},{"key":"2119_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/00007691-200108000-00019","volume":"23","author":"B Rodriguez de la Torre","year":"2001","unstructured":"Rodriguez de la Torre, B. et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther. Drug Monit. \n                           23, 435\u2013440 (2001).","journal-title":"Ther. Drug Monit."},{"key":"2119_CR18","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/archpsyc.1980.01780240087010","volume":"37","author":"P Thoren","year":"1980","unstructured":"Thoren, P. et al. Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch. Gen. Psychiatry \n                           37, 1289\u20131294 (1980).","journal-title":"Arch. Gen. Psychiatry"},{"key":"2119_CR19","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/brain\/awm038","volume":"130","author":"R Magliozzi","year":"2007","unstructured":"Magliozzi, R. et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain \n                           130, 1089\u20131104 (2007).","journal-title":"Brain"},{"key":"2119_CR20","doi-asserted-by":"publisher","first-page":"e57820","DOI":"10.1371\/journal.pone.0057820","volume":"8","author":"J Romme Christensen","year":"2013","unstructured":"Romme Christensen, J. et al. Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. PLoS ONE \n                           8, e57820 (2013).","journal-title":"PLoS ONE"},{"key":"2119_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1472-8206.1992.tb00094.x","volume":"6","author":"H Marty","year":"1992","unstructured":"Marty, H. et al. Compared plasma and brain pharmacokinetics of clomipramine and its metabolite demethylclomipramine in two strains of mice (NMRI and CD1). Fundam. Clin. Pharmacol. \n                           6, 49\u201357 (1992).","journal-title":"Fundam. Clin. Pharmacol."},{"key":"2119_CR22","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1177\/1352458511400476","volume":"17","author":"S Al-Izki","year":"2011","unstructured":"Al-Izki, S., Pryce, G., Jackson, S. J., Giovannoni, G. & Baker, D. Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Mult. Scler. \n                           17, 939\u2013948 (2011).","journal-title":"Mult. Scler."},{"key":"2119_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jneuroim.2008.05.034","volume":"201-202","author":"DW Hampton","year":"2008","unstructured":"Hampton, D. W. et al. An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. J. Neuroimmunol. \n                           201-202, 200\u2013211 (2008).","journal-title":"J. Neuroimmunol."},{"key":"2119_CR24","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1136\/jnnp-2014-307712","volume":"85","author":"L Haider","year":"2014","unstructured":"Haider, L. et al. Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J. Neurol. Neurosurg. Psychiatry \n                           85, 1386\u20131395 (2014).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2119_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrneurol.2014.37","volume":"10","author":"MA Friese","year":"2014","unstructured":"Friese, M. A., Schattling, B. & Fugger, L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat. Rev. Neurol. \n                           10, 225\u2013238 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"2119_CR26","doi-asserted-by":"publisher","first-page":"22558","DOI":"10.3390\/ijms141122558","volume":"14","author":"EC Lauterbach","year":"2013","unstructured":"Lauterbach, E. C. Neuroprotective effects of psychotropic drugs in Huntington\u2019s disease. Int. J. Mol. Sci. \n                           14, 22558\u201322603 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"2119_CR27","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1073\/pnas.0409402102","volume":"102","author":"TS Tang","year":"2005","unstructured":"Tang, T. S. et al. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington\u2019s disease. Proc. Natl. Acad. Sci. USA \n                           102, 2602\u20132607 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2119_CR28","doi-asserted-by":"publisher","first-page":"e50138","DOI":"10.1371\/journal.pone.0050138","volume":"7","author":"HY Lin","year":"2012","unstructured":"Lin, H. Y. et al. Desipramine protects neuronal cell death and induces heme oxygenase-1 expression in Mes23.5 dopaminergic neurons. PLoS ONE \n                           7, e50138 (2012).","journal-title":"PLoS ONE"},{"key":"2119_CR29","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1111\/bph.12631","volume":"171","author":"S Di Prisco","year":"2014","unstructured":"Di Prisco, S. et al. Acute desipramine restores presynaptic cortical defects in murine experimental autoimmune encephalomyelitis by suppressing central CCL5 overproduction. Br. J. Pharmacol. \n                           171, 2457\u20132467 (2014).","journal-title":"Br. J. Pharmacol."},{"key":"2119_CR30","doi-asserted-by":"crossref","unstructured":"Koch M. W., Glazenborg A., Uyttenboogaart M., Mostert J., De Keyser J. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst. Rev., Cd007295 (2011).","DOI":"10.1002\/14651858.CD007295.pub2"},{"key":"2119_CR31","doi-asserted-by":"publisher","first-page":"647","DOI":"10.5483\/BMBRep.2011.44.10.647","volume":"44","author":"DW Kim","year":"2011","unstructured":"Kim, D. W. et al. Imipramine enhances neuroprotective effect of PEP-1-Catalase against ischemic neuronal damage. BMB Rep. \n                           44, 647\u2013652 (2011).","journal-title":"BMB Rep."},{"key":"2119_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.euroneuro.2007.05.002","volume":"18","author":"CH Peng","year":"2008","unstructured":"Peng, C. H. et al. Neuroprotection by imipramine against lipopolysaccharide-induced apoptosis in hippocampus-derived neural stem cells mediated by activation of BDNF and the MAPK pathway. Eur. Neuropsychopharmacol. \n                           18, 128\u2013140 (2008).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"2119_CR33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.expneurol.2008.10.001","volume":"215","author":"MP Singh","year":"2009","unstructured":"Singh, M. P. et al. Quinpramine is a novel compound effective in ameliorating brain autoimmune disease. Exp. Neurol. \n                           215, 397\u2013400 (2009).","journal-title":"Exp. Neurol."},{"key":"2119_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11481-011-9309-0","volume":"7","author":"X Hu","year":"2012","unstructured":"Hu, X. et al. Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation. J. NeuroImmune Pharmacol. \n                           7, 187\u2013201 (2012).","journal-title":"J. NeuroImmune Pharmacol."},{"key":"2119_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/2051-5960-1-84","volume":"1","author":"DW Hampton","year":"2013","unstructured":"Hampton, D. W. et al. Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis. Acta Neuropathol. Commun. \n                           1, 84 (2013).","journal-title":"Acta Neuropathol. Commun."},{"key":"2119_CR36","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.neuropharm.2008.06.045","volume":"55","author":"J Hwang","year":"2008","unstructured":"Hwang, J. et al. Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants. Neuropharmacology \n                           55, 826\u2013834 (2008).","journal-title":"Neuropharmacology"},{"key":"2119_CR37","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/sj.npp.1300195","volume":"28","author":"CM Pariante","year":"2003","unstructured":"Pariante, C. M. et al. The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology \n                           28, 1553\u20131561 (2003).","journal-title":"Neuropsychopharmacology"},{"key":"2119_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1046\/j.1471-4159.2001.00531.x","volume":"79","author":"K Hisaoka","year":"2001","unstructured":"Hisaoka, K. et al. Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. J. Neurochem. \n                           79, 25\u201334 (2001).","journal-title":"J. Neurochem."},{"key":"2119_CR39","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1006\/jaut.1998.0209","volume":"11","author":"J Zhu","year":"1998","unstructured":"Zhu, J. et al. Clomipramine and imipramine suppress clinical signs and T and B cell response to myelin proteins in experimental autoimmune neuritis in Lewis rats. J. Autoimmun. \n                           11, 319\u2013327 (1998).","journal-title":"J. Autoimmun."},{"key":"2119_CR40","doi-asserted-by":"crossref","unstructured":"Schreiber S., Bader M., Rubovitch V., Pick C.G. Interaction between methylphenidate, methadone and different antidepressant drugs on antinociception in mice, and possible clinical implications. World J. Biol. Psychiatry, 1\u20138 (2015).","DOI":"10.3109\/15622975.2015.1086492"},{"key":"2119_CR41","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1128\/AAC.00404-16","volume":"60","author":"MC Garcia","year":"2016","unstructured":"Garcia, M. C. et al. Clomipramine and benznidazole act synergistically and ameliorate the outcome of experimental chagas disease. Antimicrob. Agents Chemother. \n                           60, 3700\u20133708 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2119_CR42","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jpsychires.2013.05.028","volume":"47","author":"M Ookubo","year":"2013","unstructured":"Ookubo, M., Kanai, H., Aoki, H. & Yamada, N. Antidepressants and mood stabilizers effects on histone deacetylase expression in C57BL\/6 mice: brain region specific changes. J. Psychiatr. Res. \n                           47, 1204\u20131214 (2013).","journal-title":"J. Psychiatr. Res."},{"key":"2119_CR43","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2165\/00003088-199120060-00002","volume":"20","author":"AE Balant-Gorgia","year":"1991","unstructured":"Balant-Gorgia, A. E., Gex-Fabry, M. & Balant, L. P. Clinical pharmacokinetics of clomipramine. Clin. Pharmacokinet. \n                           20, 447\u2013462 (1991).","journal-title":"Clin. Pharmacokinet."},{"key":"2119_CR44","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9","volume":"61","author":"GG Vecil","year":"2000","unstructured":"Vecil, G. G. et al. Interleukin-1 is a key regulator of matrix metalloproteinase-9 expression in human neurons in culture and following mouse brain trauma in vivo. J. Neurosci. Res. \n                           61, 212\u2013224 (2000).","journal-title":"J. Neurosci. Res."},{"key":"2119_CR45","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.foodcont.2009.07.017","volume":"21","author":"MC Ciz","year":"2010","unstructured":"Ciz, M. C., Denev, H., Kratchanova, P., Slavov, M. & Lojek, A. Different methods for control and comparison of the antioxidant properties of vegetables. Food Control \n                           21, 518\u2013523 (2010).","journal-title":"Food Control"},{"key":"2119_CR46","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1021\/jf011480w","volume":"50","author":"B Ou","year":"2002","unstructured":"Ou, B. et al. Novel fluorometric assay for hydroxyl radical prevention capacity using fluorescein as the probe. J. Agric. Food Chem. \n                           50, 2772\u20132777 (2002).","journal-title":"J. Agric. Food Chem."},{"key":"2119_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11312","volume":"7","author":"MB Keough","year":"2016","unstructured":"Keough, M. B. et al. An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination. Nat. Commun. \n                           7, 11312 (2016).","journal-title":"Nat. Commun."},{"key":"2119_CR48","doi-asserted-by":"publisher","first-page":"310ra166","DOI":"10.1126\/scitranslmed.aab4176","volume":"7","author":"R Li","year":"2015","unstructured":"Li, R. et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci. Transl. Med. \n                           7, 310ra166 (2015).","journal-title":"Sci. Transl. Med."},{"key":"2119_CR49","doi-asserted-by":"publisher","first-page":"4580","DOI":"10.1128\/MCB.20.13.4580-4590.2000","volume":"20","author":"A Besson","year":"2000","unstructured":"Besson, A. & Yong, V. W. Involvement of p21(Waf1\/Cip1) in protein kinase C alpha-induced cell cycle progression. Mol. Cell Biol. \n                           20, 4580\u20134590 (2000).","journal-title":"Mol. Cell Biol."},{"key":"2119_CR50","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ana.23599","volume":"72","author":"LW Lau","year":"2012","unstructured":"Lau, L. W. et al. Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination. Ann. Neurol. \n                           72, 419\u2013432 (2012).","journal-title":"Ann. Neurol."},{"key":"2119_CR51","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jneuroim.2005.04.020","volume":"165","author":"F Giuliani","year":"2005","unstructured":"Giuliani, F., Fu, S. A., Metz, L. M. & Yong, V. W. Effective combination of minocycline and interferon-beta in a model of multiple sclerosis. J. Neuroimmunol. \n                           165, 83\u201391 (2005).","journal-title":"J. Neuroimmunol."},{"key":"2119_CR52","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jns.2015.08.1525","volume":"358","author":"MW Koch","year":"2015","unstructured":"Koch, M. W. et al. Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis. J. Neurol. Sci. \n                           358, 131\u2013137 (2015).","journal-title":"J. Neurol. Sci."},{"key":"2119_CR53","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.forsciint.2006.03.038","volume":"162","author":"T Shinozuka","year":"2006","unstructured":"Shinozuka, T., Terada, M. & Tanaka, E. Solid-phase extraction and analysis of 20 antidepressant drugs in human plasma by LC\/MS with SSI method. Forensic Sci. Int. \n                           162, 108\u2013112 (2006).","journal-title":"Forensic Sci. Int."},{"key":"2119_CR54","doi-asserted-by":"publisher","first-page":"898","DOI":"10.2353\/ajpath.2009.080952","volume":"174","author":"A Goncalves DaSilva","year":"2009","unstructured":"Goncalves DaSilva, A. & Yong, V. W. Matrix metalloproteinase-12 deficiency worsens relapsing-remitting experimental autoimmune encephalomyelitis in association with cytokine and chemokine dysregulation. Am. J. Pathol. \n                           174, 898\u2013909 (2009).","journal-title":"Am. J. Pathol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-02119-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-02119-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-02119-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T23:31:19Z","timestamp":1671751879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-02119-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,19]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["2119"],"URL":"https:\/\/doi.org\/10.1038\/s41467-017-02119-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,19]]},"assertion":[{"value":"6 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.F., M.K., and V.W.Y. filed a provisional patent application at the US FDA. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1990"}}